These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31403818)

  • 1. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.
    Griffith SD; Miksad RA; Calkins G; You P; Lipitz NG; Bourla AB; Williams E; George DJ; Schrag D; Khozin S; Capra WB; Taylor MD; Abernethy AP
    JCO Clin Cancer Inform; 2019 Aug; 3():1-13. PubMed ID: 31403818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer.
    Griffith SD; Tucker M; Bowser B; Calkins G; Chang CJ; Guardino E; Khozin S; Kraut J; You P; Schrag D; Miksad RA
    Adv Ther; 2019 Aug; 36(8):2122-2136. PubMed ID: 31140124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.
    Torres AZ; Nussbaum NC; Parrinello CM; Bourla AB; Bowser BE; Wagner S; Tabano DC; George D; Miksad RA
    Adv Ther; 2022 Jun; 39(6):2831-2849. PubMed ID: 35430670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.
    Stewart M; Norden AD; Dreyer N; Henk HJ; Abernethy AP; Chrischilles E; Kushi L; Mansfield AS; Khozin S; Sharon E; Arunajadai S; Carnahan R; Christian JB; Miksad RA; Sakoda LC; Torres AZ; Valice E; Allen J
    JCO Clin Cancer Inform; 2019 Jul; 3():1-15. PubMed ID: 31335166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
    Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
    Khozin S; Miksad RA; Adami J; Boyd M; Brown NR; Gossai A; Kaganman I; Kuk D; Rockland JM; Pazdur R; Torres AZ; Zhi J; Abernethy AP
    Cancer; 2019 Nov; 125(22):4019-4032. PubMed ID: 31381142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
    Kehl KL; Riely GJ; Lepisto EM; Lavery JA; Warner JL; LeNoue-Newton ML; Sweeney SM; Rudolph JE; Brown S; Yu C; Bedard PL; Schrag D; Panageas KS;
    JAMA Netw Open; 2021 Jul; 4(7):e2117547. PubMed ID: 34309669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
    Li Y; Appius A; Pattipaka T; Feyereislova A; Cassidy A; Ganti AK
    PLoS One; 2019; 14(1):e0209709. PubMed ID: 30608948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
    She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
    JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
    Davies J; Martinec M; Coudert M; Delmar P; Crane G
    Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine-Learning and Stochastic Tumor Growth Models for Predicting Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer.
    Siah KW; Khozin S; Wong CH; Lo AW
    JCO Clin Cancer Inform; 2019 Sep; 3():1-11. PubMed ID: 31539267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.
    Sorial MN; Huynh JP; Azzoli CG; Liauw JC; Brunault RD; Collins CM; Zullo AR
    Eur J Cancer; 2021 Mar; 145():234-244. PubMed ID: 33431285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes in patients with unresected stage III non-small cell lung cancer.
    Ryan KJ; Skinner KE; Fernandes AW; Punekar RS; Pavilack M; Walker MS; VanderWalde NA
    Med Oncol; 2019 Jan; 36(3):24. PubMed ID: 30706218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
    Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC.
    Ma X; Bellomo L; Magee K; Bennette CS; Tymejczyk O; Samant M; Tucker M; Nussbaum N; Bowser BE; Kraut JS; Bourla AB
    Adv Ther; 2021 Apr; 38(4):1843-1859. PubMed ID: 33674928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.